The FDA approved , and drugmaker Egalet scored some abuse-deterrent labeling, cautious as it may be. The drug's label will say it is "expected" to make abuse by injection difficult, according to an agency spokesperson. See the full story on 鶹ý later today.
The FDA has for valbenazine (Ingrezza), a VMAT2 inhibitor for tardive dyskinesia. Neither the FDA nor drugmaker Neurocrine would provide an explanation, but a company spokesperson told 鶹ý that the move is positive and that the drug is still on its priority review track, with a decision date of April 11.
Detroit spine surgeon Aria Sabit was for performing poor or unnecessary spinal surgeries in California and Michigan.
Health News Review for its shallow reporting on a single-patient immunotherapy trial of CAR-T for a brain tumor.
The New York Times shares from the front lines of the nation's opioid crisis.
More device companies, St. Jude and Boston Scientific among them, for Parkinson's. (Wall Street Journal, subscription required)
Axovant said it has of intepirdine -- a serotonin receptor antagonist intended to stimulate acetylcholine release -- for patients with mild-to-moderate Alzheimer's disease, with results expected in the third quarter of this year.